Ensol Biosciences Inc.

PPI-Regulating Short Peptide Drugs

Maximizing therapeutic effects with non-blood local injection
High specificity and pathology-specific fine regulation of target
Minimizing side effects by short half-life in blood

* PPI: Protein-Protein Interaction

Clinical Stage Pharmaceutical

Degenerative disc treatment drug P2K – US FDA Phase 3
Osteoarthritis treatment drug E1K – Korea MFDS Phase 2
TNBC anti-cancer drug C1K – Korea MFDS Phase 1

New Drugs For Medical Unmet Needs

New drugs treating diseases with no therapeutic alternatives;
Degenerative disc, Osteoarthritis, TNBC,
Alzheimer's disease, Type 1 diabetes, Atopic dermatitis

* TNBC: Triple Negative Breast Cancer

Notice

P2K 1차 선급금 입금 공지사항	2024-08-08
[공지] P2K 적응증 확대 기술 수출 계약 관련 질문에 대한 답변	2024-07-10
[공지] 골관절염치료제 E1K 임상 결과 설명	2024-06-25
[공지] 임상 단계 주요 파이프라인의 현황 및 계획	2024-05-29

Ensol News

[기사] 바이오 투자 빙하기... 엔솔바이오에 투자 대거 …	2024-08-23
[기사] 엔솔바이오사이언스, ㈜마그나인베스트로부터 15억 …	2024-08-13
[기사] 엔솔바이오, 기술이전 이어 투자유치까지 '한고비'…	2024-08-13
[기사] 엔솔바이오사이언스, IR 본부장에 곽성권 전무 전…	2024-07-22

Technology Platform

Service/Product

IR/PR

Customer Inquiry

New Drug Pipeline

Introducing Ensol’s New Drug Pipeline

New Drug Discovery Service(CDO)

Contract Development
Organization

New Drug
CMC service

Chemistry,
Manufacturing & Controls

Material Analysis/Synthesis

EnsolBio
Resource Center